Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 14/20 | 0.42 |
| ▸ | TK1 | P04183 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535813 | 0.90 | TYMP (0.41) | TYMPTK2TK1 | |
| SCHEMBL6850137 | 0.89 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL31723482 | 0.89 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL315534 | 0.89 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL5888977 | 0.89 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL17090761 | 0.89 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL1738385 | 0.89 | TYMP (0.44) | TYMPTK2TK1 | |
| SCHEMBL1738383 | 0.89 | TYMP (0.44) | TYMPTK2TK1 | |
| SCHEMBL7267312 | 0.88 | TK2 (0.42) | TYMPTK2TK1 | |
| SCHEMBL1738390 | 0.88 | TYMP (0.45) | TYMPTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270024-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180094260-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | KASTLE THERAPEUTICS, LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170355986-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | KASTLE THERAPEUTICS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9476051-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150232838-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | COMERICA BANK | 2015-08-20 | — | — | US | disclosed |
| US-20150167008-A1 | ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2365094-B1 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20150105440-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | GENZYME CORPORATION (US) | 2015-04-16 | — | — | US | disclosed |
| EP-2174945-B1 | Antisense modulation of apolipoprotein B expression | GENZYME CORP (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8993529-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-5948902-A | NATURALLY PRESENT CELLULAR ENZYMES WHICH HAVE BEEN IMPLICATED IN ABNORMAL CEL PROLIFERATION, CARCINOGENESIS AND TUMOR FORMATION. | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1999-09-07 | — | — | US | disclosed |
| US-5945290-A | OLIGONUCLEOTIDES TARGETED AGAINST SPECIFIC NUCLEIC ACIDS; FOR ANTITUMOR/ANTICARCINOGENIC AGENTS; DIAGNOSIS AND THERAPY OF RELATED DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | disclosed |
| US-5877309-A | NUCLEOTIDE SEQUENCES WHICH SUPPRESS EXPRESSION OF JUN N-TERMINAL KINASE ONCOGENE BY COMPLEMENTARY HYBRIDIZATION; ANTIPROLIFERATIVE AGENTS, ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTSAND ANTIMETASTASIS AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5872242-A | MRNA ENCODERS FOR DIAGNOSIS AND RESEARCH | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1998049348-A1 | OLIGONUCLEOTIDES FOR ENHANCED BIOAVAILABILITY | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5801154-A | Antisense oligonucleotide modulation of multidrug resistance-associated protein | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5789573-A | OLIGOMERS WHICH HYBRIDIZE WITH ENDCAPPED TARGET RNA TRANSCRIPT | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |